April Bio is a clinical-stage drug developer with no marketed products of its own. Its core asset is SAFA, an antibody half-life extension platform that binds a drug to serum albumin to lengthen the interval between doses. The company earns money by out-licensing candidates built on this platform to overseas pharmaceutical firms, collecting upfront payments and milestones (APB-A1 to Lundbeck, APB-R3 to Evommune). In May 2026, a SAFA-based technology license signed with Yuhan in 2022 was terminated early, but the company disclosed that it has no obligation to return the upfront payment already received and said it would redirect its research capacity to new pipelines. The notable point of late is that its strengths lie in a track record of already out-licensing to global pharma and a solid financial footing (net cash, current ratio of 174.9x), while the Yuhan termination removed one leg of its partnerships and much of the remaining value now hinges on the binary events of Lundbeck's and Evommune's clinical results, so whether milestone payments and clinical milestones actually arrive is the key thing to watch.
At-a-glance assessment financial health · growth · profitability · valuation
- The most recent full-year net result was a loss.
- Revenue fell 92.1% year over year (3-year trend: mixed).
- Most recent quarter (Q1 2026) revenue was 66.6% lower than a year earlier.
- ROE is -10.1% (total-net basis). It is above the sector average.
- Operating margin is -334.4%.
- P/E is hard to compute here, so this is read on P/B.
Ownership & governance As of 2025-12-31
Largest shareholder Cha Sang-hoon 19.07% (individual)
Controlling bloc incl. related parties 19.57%
With the controlling bloc holding 20%, control is maintained but the free float is relatively large.
🔎 In-depth analysis
- April Bio is a clinical-stage drug developer with no marketed products of its own.
- Its core asset is a platform technology called SAFA, which extends the half-life of antibodies.
- By binding a drug to serum albumin so that it stays in the body longer, the technology lengthens the interval between doses, which is its key strength.
- The company makes money by handing over drug candidates built on this platform to overseas pharmaceutical firms (out-licensing) and collecting upfront payments plus success-based milestones tied to each development stage.
- Its flagship candidate APB-A1 has been out-licensed to Denmark's Lundbeck and APB-R3 to Evommune, both currently in clinical trials.
- In other words, the size of revenue depends not on product sales but on which milestone is collected in a given year.
- The latest close is ₩26,600 and market cap is ₩622.8 billion.
- The price sits below its 20-day line (₩37,155) and its 60-day line (₩51,226).
- Trading below both its short- and mid-term moving averages, the trend is subdued.
- The RSI (a supplementary gauge that weighs the strength of gains against losses over the past 14 days on a 0-100 scale) is 29.5, close to depressed territory.
- The one-month change is -38.4%, the three-month change is -47.8%, and the price stands -63.7% below its 52-week high.
- Relative strength versus the KOSDAQ is 71 (on a 1-99 scale, computed from returns against the index over the past year with recent performance weighted more heavily; higher means stronger than the market).
- That places it in roughly the top 29% of all stocks by strength.
- Over the past three months it lagged the index by 29.9%.
- Chart interpretation is best done alongside trading volume and the dates of disclosures.
- As a clinical-stage biotech, the usual profitability and valuation metrics do not map onto it cleanly.
- In 2025 revenue was ₩2.17 billion with a net loss of ₩9.73 billion, a year with no milestone recognition.
- The P/E ratio cannot be calculated because of the loss.
- P/B comes to 6.47x and P/S to 378x, which look high, but these figures carry little meaning for this company.
- That is because the essence of its value lies not in book equity or current revenue but in the future value of its platform and out-licensed pipeline.
- Its financial footing, by contrast, is solid.
- Current assets stand at about ₩94.7 billion, most of it cash-like, and the company is in a net cash position (net debt of -₩6.58 billion), holding more cash than borrowings.
- The current ratio is 174.9x, meaning there is essentially no short-term payment burden.
- In short, it is a structure with low near-term funding risk that covers research costs out of cash.
- The earnings trend should be understood as a seesaw driven by the presence or absence of milestones rather than as 'growth.' In 2024 the company was profitable, with revenue of ₩27.5 billion and net profit of ₩20.0 billion, because out-licensing upfront payments and milestones were recognized that year.
- In 2025 those one-off gains dropped out, and it reverted to revenue of ₩2.17 billion and a net loss.
- Reading this reversion purely as 'deteriorating results' would be a misunderstanding.
- By nature, milestones are recognized in bursts in particular years and drop out the following year.
- In the first quarter of 2026 revenue was ₩725 million and operating loss was ₩2.19 billion, but net profit was slightly positive (₩200 million) thanks to financial income generated by the cash on hand.
- Going forward, the direction of results will be determined not by the quarterly trend but by the clinical progress of Lundbeck and Evommune and whether new partnerships are signed.
- In May 2026, the SAFA-based fusion protein technology license and joint research and development agreement signed with Yuhan in 2022 was terminated early by mutual agreement of both companies.
- The company disclosed that it has no obligation to return the upfront payment already received and stated its direction of redirecting research capacity into new pipelines based on its next-generation platform.
- This termination is a separate matter from the ongoing Lundbeck and Evommune out-licensing deals.
- Beyond this there were numerous large-holding and executive shareholding disclosures, and in March the routine annual report and shareholder meeting-related disclosures followed.
- This is a company driven by pipeline events rather than earnings metrics.
- The strengths are clear.
- It has a track record of already out-licensing to global pharmaceutical firms via the SAFA platform.
- With net cash and a current ratio of 174.9x, its financial footing is ample and funding pressure on trials is low.
- On the other hand, the cautions are just as clear.
- The Yuhan termination removed one leg of its partnerships.
- Much of the remaining value hinges on the binary events of Lundbeck's and Evommune's clinical results.
- If the clinical data is positive or a new out-licensing deal is struck, there is considerable room for re-valuation, but if the data disappoints, the downside could be large too.
- Ultimately, whether milestone payments and clinical milestones actually materialize is the key thing to watch.
🔎 Valuation vs peers Inconclusive
Domestic-listed clinical-stage antibody and platform drug developers, whose business model of generating revenue from out-licensing upfronts and milestones without a marketed product of their own is similar.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| April Bio | 0.00x | 6.47x | -10.10% |
For this company it is hard to draw an undervalued/overvalued line using P/E, P/B, or P/S, because revenue and profit swing sharply year to year depending on when milestones are recognized. Even the gap between the 2024 profit (net profit of ₩20.0 billion) and the 2025 loss (-₩9.7 billion) reflects the presence or absence of milestones rather than deteriorating operations. Taking last year's P/B of 8.5x and P/S of 378x at face value to declare it 'expensive' is therefore inappropriate. Its real value is better assessed through the clinical progress of the pipeline out-licensed to Lundbeck and Evommune, the possibility of new out-licensing, and the size of its net cash. Because the value is heavily swayed by the binary events of clinical results, an inconclusive verdict is the honest conclusion for now.
Price history Close · MA20 · MA60
The latest close is ₩26,600 and the market capitalization is ₩622.8 billion. The price sits below its 20-day moving average (₩37,155) and below its 60-day moving average (₩51,226). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 29.5, near oversold territory. The one-month change is -38.4%, the three-month change is -47.8%, and the position relative to the 52-week high is -63.7%. Relative strength versus the KOSDAQ is 71 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 71% of all stocks. Over the past three months it lagged the index by 29.9%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -29.92% / 6M -38.53% / 12M +53.54%
Key metrics vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 6.47x is in line with the sector median (7.05x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
The operating margin is -334.4%. The debt ratio is 100.8%, so the financial structure is moderate.
Growth FY2025 · annual report (separate)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $0 | $18.2M | $1.4M | -92.11% |
| Operating profit | -$8.9M | $11.2M | -$4.8M | -143.06% |
| Net profit | -$9.4M | $13.3M | -$6.4M | -148.63% |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $15.5M | $132,555 | $0 | $18.2M | $1.4M |
| Operating profit | $2.9M | -$7.6M | -$8.9M | $11.2M | -$4.8M |
| Net profit | -$34.9M | -$5.9M | -$9.4M | $13.3M | -$6.4M |
| Revenue CAGR | 4-yr avg -44.80% | ||||
Revenue fell 92.1% year over year (2023 ₩0 → 2024 ₩27.5 billion → 2025 ₩2.2 billion), and the three-year trend is 'mixed'. Operating profit fell 143.1% year over year. Over the 5 years on record, revenue compound annual growth (CAGR) is -44.8%. In the most recent quarter (Q1 2026), revenue was 66.6% lower than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- —
Points to watch
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
- Revenue fell 92.1% year over year (3-year trend: mixed).
Recent news & events searched · sourced
- 2026-05-04FilingThe SAFA-based fusion protein technology license and joint R&D agreement signed with Yuhan in 2022 was terminated early by mutual agreement. No obligation to return the upfront payment already received.A short-term negative in that one leg of the partnerships disappears, but there is no financial loss since there is no obligation to return the upfront. A mid-term inflection point as research capacity is redirected into next-generation pipelines. Source
- 2026-05-15EarningsQ1 2026 quarterly report. Revenue of ₩725 million, operating loss of ₩2.19 billion, and net profit of ₩200 million (reflecting financial income on cash holdings).With no milestones, operations were in the red, but the net result was slightly positive thanks to interest income on net cash. Confirms the cash cushion. Source
- 2026-03-13Earnings2025 annual report. Revenue of ₩2.17 billion and a net loss of ₩9.73 billion finalize the 2025 results for a year with no milestone recognition. A net cash structure with current assets of about ₩94.7 billion was maintained.A reversion versus the 2024 profit (net profit of ₩20.0 billion), but this is a structural swing tied to the presence or absence of milestones. The financial footing is solid. Source
- 2026-06-10FilingFiling of a report on large holdings of stock (abbreviated form). Reflects changes in major shareholders' stakes.Reference information on the shareholding structure. Limited impact on the actual business. Source
Figure cross-check computed ↔ external
Recent filings
- 2026-06-10OwnershipOwnership-change filing
- 2026-05-15PeriodicQuarterly report
- 2026-05-04Disclosure
- 2026-04-16OwnershipOfficers'/major-shareholders' holdings report
- 2026-04-16OwnershipOfficers'/major-shareholders' holdings report
- 2026-04-16OwnershipOfficers'/major-shareholders' holdings report
- 2026-04-09OwnershipOwnership-change filing
- 2026-03-25Shareholders' meeting notice
- 2026-03-13PeriodicAnnual business report
- 2026-03-13Audit report
- 2026-03-10Disclosure
- 2026-03-10Shareholders' meeting notice
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.